JP2017502003A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502003A5
JP2017502003A5 JP2016538037A JP2016538037A JP2017502003A5 JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5 JP 2016538037 A JP2016538037 A JP 2016538037A JP 2016538037 A JP2016538037 A JP 2016538037A JP 2017502003 A5 JP2017502003 A5 JP 2017502003A5
Authority
JP
Japan
Prior art keywords
phe
pro
tyr
aib
nal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016538037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502003A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/077240 external-priority patent/WO2015086686A2/en
Publication of JP2017502003A publication Critical patent/JP2017502003A/ja
Publication of JP2017502003A5 publication Critical patent/JP2017502003A5/ja
Pending legal-status Critical Current

Links

JP2016538037A 2013-12-13 2014-12-10 プロテアーゼ耐性ペプチド Pending JP2017502003A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915662P 2013-12-13 2013-12-13
US61/915,662 2013-12-13
PCT/EP2014/077240 WO2015086686A2 (en) 2013-12-13 2014-12-10 Protease resistant peptides

Publications (2)

Publication Number Publication Date
JP2017502003A JP2017502003A (ja) 2017-01-19
JP2017502003A5 true JP2017502003A5 (https=) 2017-12-28

Family

ID=52021207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016538037A Pending JP2017502003A (ja) 2013-12-13 2014-12-10 プロテアーゼ耐性ペプチド

Country Status (11)

Country Link
US (1) US20160318987A1 (https=)
EP (2) EP3415526A1 (https=)
JP (1) JP2017502003A (https=)
KR (1) KR20160098406A (https=)
CN (1) CN105849123A (https=)
AU (1) AU2014363547A1 (https=)
BR (1) BR112016013157A2 (https=)
CA (1) CA2933405A1 (https=)
MX (1) MX2016007407A (https=)
SG (1) SG10201805039UA (https=)
WO (1) WO2015086686A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI726889B (zh) 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
EP3368556B1 (en) * 2015-10-28 2024-04-10 Tufts University Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
AU2017277594A1 (en) 2016-06-09 2019-02-07 Medimmune Limited Protease-resistant mono-lipidated peptides
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
RS63523B1 (sr) 2018-04-05 2022-09-30 Sun Pharmaceutical Ind Ltd Novi glp-1 analozi
JP7736315B2 (ja) * 2020-03-31 2025-09-09 アンタロス メディカル アクティエボラーグ イメージング及び治療目的のキレート部分を含む選択的gip受容体アゴニスト
US20240067693A1 (en) * 2020-12-16 2024-02-29 Medimmune Limited Polypeptides and uses thereof
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽
CN121248731A (zh) * 2025-09-18 2026-01-02 内蒙古博睿精创科技有限公司 一种长效降糖减重的多靶点多肽化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69922043T2 (de) * 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
CN101379075B (zh) * 2006-02-08 2013-05-15 隆萨股份公司 类胰高血糖素肽的合成
US20100022457A1 (en) * 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US20090318353A1 (en) * 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
WO2009125424A2 (en) * 2007-12-11 2009-10-15 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
DE602009000324D1 (de) * 2008-04-18 2010-12-23 Hoffmann La Roche Alpha-N-Methylierung von Aminosäuren
WO2011048614A2 (en) * 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
US20130143800A1 (en) * 2011-11-07 2013-06-06 Research Development Foundation Combination therapies to treat diabetes
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
EP2928562A4 (en) * 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE

Similar Documents

Publication Publication Date Title
JP2017502003A5 (https=)
AR096162A1 (es) Péptidos terapéuticos
TWI455721B (zh) 癌疫苗組合物
NZ600732A (en) Oxyntomodulin peptide analogue
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
RU2021134101A (ru) Модифицированная j-цепь
MX2019001925A (es) Proteina de fusion del factor viii de la coagulacion sanguinea humana altamente glicosilada y metodo de fabricacion y aplicacion del mismo.
PE20121393A1 (es) Analogo peptidico de oxintomodulina
PH12013500050A1 (en) Anticancer fusion protein
NZ624533A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
WO2015188132A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
JP2013515055A5 (https=)
MX2024006356A (es) Metodos para predecir la utilidad de modificaciones de aminoacidos especificas de una enfermedad para inmunoterapia
PH12014501083A1 (en) Anticancer fusion protein
JP2017535527A5 (https=)
JP2017522362A5 (https=)
NZ708990A (en) Method for activating helper t cell
AR096927A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
JP2019525753A5 (https=)
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2014008028A (es) Proteina de fusion anticancerigena.
SA521421371B1 (ar) لقاحات الببتيد
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof